WINTON GROUP Ltd Has $1.19 Million Stake in Corcept Therapeutics Incorporated (NASDAQ:CORT)

WINTON GROUP Ltd increased its position in Corcept Therapeutics Incorporated (NASDAQ:CORT) by 23.6% during the fourth quarter, Holdings Channel.com reports. The firm owned 23,675 shares of the biotechnology company’s stock after buying an additional 4,520 shares during the quarter. WINTON GROUP Ltd’s holdings in Corcept Therapeutics were worth $1,193,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of CORT. Segall Bryant & Hamill LLC bought a new position in shares of Corcept Therapeutics in the fourth quarter valued at $1,098,000. Vanguard Group Inc. increased its position in shares of Corcept Therapeutics by 1.1% during the fourth quarter. Vanguard Group Inc. now owns 10,115,624 shares of the biotechnology company’s stock worth $509,726,000 after acquiring an additional 109,294 shares in the last quarter. Bridge City Capital LLC raised its holdings in shares of Corcept Therapeutics by 0.9% in the 4th quarter. Bridge City Capital LLC now owns 57,892 shares of the biotechnology company’s stock worth $2,917,000 after acquiring an additional 518 shares during the last quarter. LPL Financial LLC lifted its position in Corcept Therapeutics by 47.9% in the 4th quarter. LPL Financial LLC now owns 60,682 shares of the biotechnology company’s stock valued at $3,058,000 after acquiring an additional 19,650 shares in the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new position in Corcept Therapeutics during the 4th quarter valued at about $1,340,000. Institutional investors own 93.61% of the company’s stock.

Insider Buying and Selling

In other Corcept Therapeutics news, insider Sean Maduck sold 20,000 shares of the business’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $50.39, for a total value of $1,007,800.00. Following the sale, the insider now directly owns 85,318 shares in the company, valued at $4,299,174.02. The trade was a 18.99 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Joseph K. Belanoff sold 1,974 shares of the company’s stock in a transaction on Monday, March 24th. The shares were sold at an average price of $60.83, for a total value of $120,078.42. Following the transaction, the chief executive officer now directly owns 3,017,437 shares in the company, valued at $183,550,692.71. This represents a 0.07 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 48,022 shares of company stock valued at $2,703,257. 20.50% of the stock is owned by company insiders.

Corcept Therapeutics Trading Down 3.6 %

NASDAQ CORT opened at $54.63 on Friday. The business’s fifty day moving average is $61.89 and its 200-day moving average is $54.47. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.70 and a quick ratio of 3.64. The stock has a market capitalization of $5.76 billion, a price-to-earnings ratio of 43.36 and a beta of 0.61. Corcept Therapeutics Incorporated has a one year low of $20.84 and a one year high of $75.00.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $0.26 EPS for the quarter, missing the consensus estimate of $0.37 by ($0.11). The company had revenue of $181.89 million during the quarter, compared to the consensus estimate of $200.12 million. Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. Equities research analysts predict that Corcept Therapeutics Incorporated will post 1.36 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on CORT shares. Piper Sandler lifted their target price on Corcept Therapeutics from $67.00 to $78.00 and gave the company an “overweight” rating in a research report on Thursday, February 27th. Canaccord Genuity Group increased their target price on shares of Corcept Therapeutics from $78.00 to $130.00 and gave the company a “buy” rating in a report on Thursday, January 30th. HC Wainwright restated a “buy” rating and set a $115.00 price target on shares of Corcept Therapeutics in a report on Thursday, February 27th. Finally, StockNews.com lowered shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, February 28th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, Corcept Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $99.75.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.